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Peptide YY (PYY) and enteroglucagon are produced by endocrine cells of the colonic
mucosa. PYY inhibits upper gastrointestinal motility, and enteroglucagon is trophic for small
bowel mucosa. Adaptive increase in the production and release ofthese peptides may improve
functional results after colorectal resections. We hypothesized that if segments of the colon
were resected, then production and release ofPYY and enteroglucagon would increase in the
remaining segments of bowel. Animals which underwent colonic transections and partial
resections had transient elevations of PYY up to 250 + 80 pmol/L, which dropped to control
group levels in the second week following surgery. Rats with an abdominal colectomy had
significantly greater PYY levels than all other groups from the third (208 + 30 pmol/L) to the
thirty-eighth (100 ± 16 pmol/L) week of the study. Circulating levels of enteroglucagon were
elevated to 156 ± 35 pmol/L in rats with a right hemicolectomy during the first week following
surgery. Enteroglucagon levels did not significantlyvaryin the othergroups studied. Both tissue
PYY (413 ± 33 pmol/gram) and tissue enteroglucagon (171 ± 17 pmol/gram) were signifi-
cantly elevated in the rectums ofthe ratswith an abdominalcolectomy, ascompared to allother
groups. The elevated tissue levels may thus account for the ability to maintain elevated plasma
PYY. Double immunogold labeling of endocrine cells in the colorectal tissue for PYY and
enteroglucagon revealed both peptides within the same endocrine cells and secretory granules.
These studies support the hypothesis that circulating levels of PYY are elevated after major
colonicresections and suggest that L-type endocrine cells mayparticipate in adaptive responses
which improve intestinal function following colonic surgery.
INTRODUCTION
The colon acts as an endocrine organ by release of such bioactive peptides as
peptide YY (PYY) and enteroglucagon. PYY and enteroglucagon are contained
within mucosal endocrine cells, called L cells [1,2,3,4,5]. These peptides are pri-
marily located within the distal gastrointestinal tract [3,6,7,8,9,10,11]. PYY inhibits
upper gastrointestinal tract motility, while enteroglucagon is trophic for small bowel
mucosa. Thus, the colon contains peptideswhich influence proximal gastrointestinal
function.
Tatemoto and Mutt first isolated PYY by means of its C-terminal amide from
porcine small bowel [12,13]. It is a 36 amino acid straight-chain peptide, named
peptide YY because ofits N- and C-terminal tyrosine (Y) residues [13]. Infusion of
PYY into healthy human subjects significantly inhibits gastric acid and pepsinogen
secretion, delays gastric emptying, and inhibits small bowel motility [14,15]. In
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human surgical specimens, Adrian et al. found the highest concentrations of PYY
within the terminal ileum, large bowel, and up to 480 pmol/gram in the rectum, in
contrast to the less than 6 pmol/gram of PYY within the stomach, duodenum, and
small bowel [9,11]. In rats, Miyachi et al. found tissue levels ofPYY were greatest in
the distal half of the colon (449 pmol/gram of tissue) and less than 9 pmol/gram in
tissue proximal to the ileum [10].
Unger et al. first detected enteroglucagon in canine gastric mucosa, using a
cross-reacting pancreatic glucagon radioimmunoassay, in 1961 [16]. This enteric
source ofpancreatic glucagon-like immunoreactivity, or enteroglucagon, consistsofa
69 amino acid peptide, glicentin/proglucagon, and a more biologically active 37
amino acid C-terminal degradation product, oxyntomodulin [6,17,18]. The 29 amino
acid sequence of pancreatic glucagon is contained within the N-terminal portion of
oxyntomodulin [17]. Enteroglucagon, as the term is used within this paper, describes
both the glicentin and oxyntomodulin detected by current radioimmunoassay tech-
niques [8]. Circulating enteroglucagon levels strongly correlate with enhanced
growth rate ofthe small bowel mucosa, following small bowel resection [19,20,21,22],
and enteroglucagon-secreting tumors are associated with villous hypertrophy [23].
Enteroglucagon does not display the glycogenolytic and hyperglycemic properties of
pancreatic glucagon [24,25,26]. Using human surgical specimens, Ghatei et al. found
the greatest tissue concentration in the ileum (275 pmol/gram) as compared to the
jejunum (58 pmol/gram) and colon (79 pmol/gram) [8]. In rats, Kervran et al. found
that enteroglucagon distributionwassimilar,withconsiderablymorepeptide present
in the ileum (197 pmol/gram), as compared to the duodenum (23 pmol/gram) and
cecum (71 pmol/gram) [6].
Partial and total large bowel resections are frequently performed each year for
patients with colon cancer, inflammatory bowel disease, and familial polyposis coli.
Functional results are often poor in the earlypost-operative period but improvewith
time. Typically, water absorption is diminished and stool frequency is increased.
Function slowly improves, reaching a stable plateau one year after surgery. Presum-
ably, compensatory mechanisms evolve, in the year following operation, which lead
to improvedwaterabsorption and decreased stoolfrequency. The mechanismswhich
account for this improved function, however, have notbeen characterized.
In previous studies, we have demonstrated thatpostprandial plasma levels ofPYY
and ilealpouch tissue levels ofPYY and enteroglucagonwere elevated oneyear after
total proctocolectomy and ileal pouch-anal anastomosis [27]. It is possible that this
increase in PYY and enteroglucagon represents an adaptive response which serves
to slow small bowel transit and to promote mucosal growth. Both ofthese responses
may contribute to the improving functional resultswhich evolve in the yearfollowing
this operation.
In the present study, we speculated that an adaptive response in plasma and tissue
levels of PYY and enteroglucagon similar to that observed after total proctocolec-
tomy and ileo-anal anastomosis might occur after partial or total resections of the
colon. We hypothesized that ifsegments ofthe colon were resected, then production
and release ofPYY and enteroglucagonwould increase in the remaining segmentsof
bowel. Therefore, the specific aims of this study were to measure changes in plasma
and tissue levels of PYY and enteroglucagon following partial and subtotal colec-
tomy in rats. In addition, immunogold double-labeling for both PYY and enteroglu-
cagon ofcolonic endocrine cellswas examined to determine if, in rats, these peptides
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co-localized within the same endocrine cells and the same secretory granules.
Co-localization of PYY and enteroglucagon within the same cells and secretory
granules would suggest that any observed increase in plasma or tissue levels ofthese
peptides represented a generalized L-type endocrine cell response.
METHODS
Operation
The protocols used in this study were approved by the Animal Investigations
Committee of the institutions. Male Wistar rats (Charles River Laboratories) were
anesthetized with an intramuscular injection of ketamine HCl (75 mg/kg). An
abdominal laparotomy was performed. The bowel was transected or resected, and
appropriate vessels were ligated and divided. Five milliliters of 0.9 percent NaCl
were administered intraperitoneally during the abdominal closure in order to
maintain a positive fluid balance. The rats were allowed immediate access to water
and allowed to feed 12 hours later.
Calculation ofWeight and Survival
Whole-body weights (grams) of the rats were recorded at the time of blood
sampling. Weight measurements of the rats in the first week were subtracted from
theweight ofeach subsequentweek to establish theweight increasesoccurring; these
were also calculated as a percentage oftheweek 1 bodyweight.
The percentage survival ofanimals was measured from the end ofthe firstweekof
the study in order to discount acute surgical complications from the calculation.
SerialBlood Sampling
All blood samples (1.5 ml) were taken by tail vein phlebotomy, in tubes containing
aprotinin (0.1 mg) and EDTA (2 mg). After centrifugation (1,200 rpm, five minutes,
4°C), plasma was separated and stored at -20°C until peptide analysis could be
performed.
Tissue Sampling
At sacrifice, tissue samples (approximately one gram) were removed from the
terminal ileum, ascending colon, descending colon, rectum, and anastomosis site for
peptide content analysis. The tissue samples were weighed and then suspended in 10
ml/g tissue weight of0.5 M glacial acetic acid in polypropylene tubes and boiled in a
water bath for 15 minutes, according to the methods of Adrian et al. [11]. These
extracts were then stored at -20°C for later peptide analysis.
IMMUNOGOLD DOUBLE-LABELING OF ENDOCRINE CELLS
The cellular localization of PYY and enteroglucagon in rat colorectal tissue was
investigated, using immunogold double-labeling techniques [28]. Tissues from nor-
mal rat colon and rectum were fixed in a mixture of 4 percent formaldehyde and 0.5
percent glutaraldehyde in phosphate buffer, pH 7.4, and subsequently dehydrated
and embedded in Lowicryl K4M (Polysciences, Inc., Warrington, PA) or Epox 812
(Fullam Inc. Latham, NY). Thin sectionswere placed on formvar-coated nickel grids
and incubated on drops of antibody solutions. Primary incubation was carried out
with a mixture of (1) rabbit anti-PYY antiserum number B52 (Milab, Malmo,
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Sweden) and (2) mouse monoclonal anti-glucagon antibodynumber GLU-001 (Novo
Biolabs, Danbury, CT). The anti-glucagon antibody was directed against both
pancreatic glucagon and enteroglucagon and thus revealed glucagon-like immunore-
activity (GLI). Antibodybinding siteswere detectedby a secondary incubationwith a
mixture of (1) goat-anti-rabbit IgG-gold (GAR G5; Jansson, Piscataway, NJ) and (2)
goat-anti-mouse IgG-gold (GAMIgG G15; Jansson). Sections were contrasted with
aqueous uranyl acetate and viewed in a Philips 300 electron microscope. Control
sections were incubated with primary antisera adsorbed with an excess of synthetic
PYY or glucagon.
Radioimmunoassays-PYY
Concentrations of PYY were measured, using a well-characterized radioimmuno-
assay, which has been previously validated for rat PYY [11,29]. The antibody (Y-21)
was raised in a rabbit immunized with pure, unconjugated, natural PYY. This
antiserum is added to give a final dilution of 1:128,000, a concentration which binds
50 percent of 1 fmol iodinated PYY. PYY is iodinated by conventional chloramine T
oxidation and labeled PYY purified using high-resolution, reverse-phase, high-
pressure liquid chromatography. The assay detects changes between adjacent tubes
of0.4 fmol with 95 percent confidence.
Enteroglucagon
This assay system has previously been validated for rat enteroglucagon and
described in detail [3,8]. Total glucagon immunoreactivitywas measured, utilizing an
antibody (GL-77) which fully recognizes pancreatic glucagon and enteroglucagon,
the antibody being N-terminally directed. Pancreatic glucagon was measured utiliz-
ing the antibody RCS-5, which recognizes only pancreatic glucagon, the antibody
beingC-terminally directed. In the isolatedvenous effluent samples and rat resection
tissue samples, there was no potential source of pancreatic glucagon, and the
enteroglucagon concentrations could then be measured directly with antibody
GL-77. In plasma samples, the pancreatic glucagon is subtracted from the total
glucagon immunoreactivity to derive a value for enteroglucagon. The assay shows no
significant cross-reaction with related peptides (secretin, VIP, PHI, GRF, and GIP)
and detects changes of0.2 fmol/tube with 95 percent confidence.
StatisticalMethods
The data analysis was performed using the SYSTAT computer software package
[30]. Plasma and tissue peptide measurements were subjected to a Bartlett's test for
homogeneity ofthevariances. For those comparisons with a significant F (p < 0.05),
data were tested by a Tukey test in order to determine significant differences
between the control group and the experimental groups. Plasma peptide levels were
compared at each time point. Tissue peptide levels were compared at each sampling
site; tissue peptide levels were also compared between the different sampling sites,
within each experimental group.
ExperimentalDesign
The rats were divided into various experimental groups. Control rats underwent
no surgery. Two groups ofrats underwent transections and the bowel was reapproxi-
mated with no loss of tissue. The first group underwent a jejunal transection 10 cm
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TABLE 1
The Increase in Body Weight (Grams) from the First Week ofthe Study for the Control, Transection,
and Resection Groups of Rats
Weeks After Surgery
Surgery n 1 2 3 6 12 Sacrifice
Controls 7 0 37 ± 2 (22) 64 ± 3 (38) 129 ± 3 (76) 187 ± 4 (110) 223 ± 13 (131)
Jejunal 6 0 36 ± 3 (19) 59 ± 4 (31) 127 ± 4 (68) 177 ± 5 (95) 223 ± 5 (120)
transection
Colonic 7 0 27 10(13) 51 ± 10(25) 94 ± 10(45) 129 ± 11 (61) 169 ± 11 (79)
transection
Right colectomy 5 0 46 ± 7 (31) 72 ± 10 (50) 135 ± 12 (93) 190 ± 15 (132) 226 ± 14 (155)
Left colectomy 7 0 34 1 (18) 65 ± 3 (34) 126 ± 7 (66) 175 ± 5 (92) 218 ± 7 (115)
Subtotal 10 0 14 ± 4 (11) 25 ± 5 (19) 64 ± 7 (45) 102 ± 7 (73) 168 ± 12 (120)
colectomy
Results are presented as mean ± SEM. The percentage increase in bodyweightoverthe initialweight
is indicated in parentheses.
from the ligament of Trietz, and the second group underwent a colon transection
between the right and middle colic arteries. Three groups of rats underwent bowel
resections and the remaining bowel was anastomosed. In the right hemicolectomy
group, the distal ileum was transected 2 cm from the ileocecal valve and the colon
transected just proximal to the middle colic artery. In the left hemicolectomy group,
the rectum was divided so as to preserve the distal two-thirds of the rectum and the
colon transectedjust distal to the middle colic artery. In the abdominal colectomy or
subtotal colectomy group, the rectum was divided as in the left hemicolectomy group
and the terminal ileum divided 2 cm from the ileocecalvalve.
Blood samples from a group of normal rats (n = 18) were used to establish basal
levels of the peptides, so as not to compromise survival of those rats used in the
surgical model. Blood samples were taken at one, two, three, six, 12, and 38 weeks
following surgery. Tissue sampleswere taken at sacrifice. In addition, threegroups of
normal ratswere bledweeklyfor one, two, and three weeks in a staggered manner in
order to establish whether the potential stress associated with the bleeding proce-
dure itselfhad any effects on peptide levels.
RESULTS
Change in Body WeightofRatsFollowing Colon Resections
The weight changes which occurred in the rats over the course of the study are
shown in Table 1. All groups gained considerable bodyweight with each subsequent
time point in the study.
Long-Term SurvivalofRats Following Surgery
The percentage of animals surviving from week 1 until the end of the study at 38
weeks was: 87 percent ofcontrols, 100 percent ofjejunal transections, 64 percent of
colon transections, 56 percent ofrighthemicolectomies, 78 percent oflefthemicolec-
tomies, and 77 percent ofsubtotal colectomies. There was no relationship ofsurvival
to the amount ofbowel resected.
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FIG. 1. The plasma PYY levels (mean + SEM) of the rats following colon
transection,jejunal transection, right hemicolectomy, left hemicolectomy, and subto-
tal colectomy as compared to a control group. When significant differences existed
between the mean plasma levels for the transection or resection groups and that for
the controls, as shown by a Bartlett's test of homogeneity and a Tukey test for
significant differences between the means, this fact has been indicated by * forp <
0.05 and ** forp < 0.01.
SerialBlood SamplingofRatsforPost-SurgicalPeptideLevels
The plasma PYY levels forcontrol, transection, and resection groups are shown in
Fig. 1. The colon transection (155 + 17 pmol/L; Tukey,p < 0.05), right hemicolec-
tomy(250 + 80pmol/L; Tukey,p < 0.01), andsubtotalcolectomy (170 + 18pmol/L;
Tukey, p < 0.05) groups had significantly elevated (Bartlett's, p < 0.0001) plasma
PYY levels in week 1 over that of controls. The PYY levels in the colon transection
group decreased byweek 2, but elevation ofPYY persisted until week 2 for the right
hemicolectomy group (Bartlett's, p < 0.0001; Tukey, p < 0.01). In contrast to the
other groups, PYY levels in the subtotal colectomy group continued to rise following
surgery and were significantly elevated over that of controls from week 2 (190 + 24
pmol/L) until week 12 (222 + 24 pmol/L) (Bartlett's,p < 0.0001; Tukey,p < 0.01).
At sacrifice (38 weeks), the PYY levels in the subtotal colectomy group had fallen
considerably, but they were still significantly elevated over those of all other groups
(100 + 16 pmol/L; Bartlett's,p < 0.0001; Tukey,p < 0.05).
The plasma enteroglucagon levels in control, transection, and resection groups are
shown in Fig. 2. Plasma enteroglucagon was significantly elevated in the right
hemicolectomygroup ascompared to controls duringweek 1 only(156 + 35 pmol/L;
Bartlett's, p < 0.001; Tukey, p < 0.01). The enteroglucagon levels of the other
groups did not significantly differ (Bartlett's) from those ofthe controls. Within each
group there was some elevation in plasma levels of enteroglucagon during the first
three weeks as compared to the latter part ofthe study.
6PYY AND ENTEROGLUCAGON AFTER COLON RESECTION
200
A -A CONTROLS *- - RIGHT
0 0 COLON HEMICOLECTOMY
O TRANSECTlON V -V LEFT
E -A JEJUNAL HEMICOLECTOMY
Q 150 TRANSECTION * * SUBTOTAL
~~~~~~~~~~COLECTOMY
100z '' T~~~~~~~~~~~
o 50 : '
WL i I I //1
0 1 2 3 6 12 38
WEEKS AFTER SURGERY
FIG. 2. The plasma enteroglucagon levels (mean + SEM) of the rats following
colon transection, jejunal transection, right hemicolectomy, left hemicolectomy, and
subtotal colectomy as compared to a control group. When significant differences
existed between the mean plasma levels for the transection or resection groups and
that for the controls, as shown by aBartlett's testofhomogeneity and aTukey test for
significant differences between the means, this fact has been indicated by * forp <
0.05 and ** forp < 0.01.
Effect ofSerialBlood Sampling on Plasma Peptide Levels in ControlRats
Three groups of control rats underwent serial blood sampling in a staggered
manner for three weeks in order to examine the effects ofthe potential stress due to
weekly phlebotomy on circulating peptide levels. These results are shown in Table 2.
There were no significant differences in plasma levels of PYY or enteroglucagon
between the various sampling times within groups 1 or 2, or between the groups at
each time point (Bartlett's).
TABLE 2
Serial Blood Sampling of Control Rats
PYY Enteroglucagon
Weeks Weeks
Group n 1 2 3 1 2 3
1 6 37+4 52±7 42±8 68±3 76±4 79±10
2 6 NA 38 7 26 4 NA 75 ± 3 60 ± 4
3 6 NA NA 28 6 NA NA 62 ± 6
PYY and enteroglucagon plasma levels were measured (pmol/liter). Results are shown as means +
SEM. Groups 2 and 3 were not sampled on theweeksmarked NA. Therewere no significant differences
between the various sampling times within groups, or between groups at each time point, as shown by
Bartlett's test.
NA = not applicable
7VUKASIN ET AL.
,--N rt CJ TRANSECTION
300
E
0-
-'200
100
0
ILEUM ASCENDING DESCENDING RECTUM
COLON COLON
500 coNTRoLs
C9 RIGHT **
HEMICOLECTOMY
400 - HEMICOLECTOMY
SUBTOTAL
COLECTOMYC
06 300
E
200
100-
0-
ILEUM ASCENDING DESCENDING RECTUM
COLON COLON
FIG. 3. The extracted tissue PYY content (pmol/gram oftissue) in samples oftissue from the
(A) control and transection groups and from the (B) control and resection groups. Results are
shown as mean + SEM. When differences of mean PYY tissue content of one group varied
significantly from that ofcontrols, according to a Bartlett's test ofhomogeneity and a Tukey test
for significant differences between the means, this fact has been indicated by ** forp < 0.01.
Peptide Extractions ofTissuesfrom ResectedRats
The results ofthe peptide extractions ofthe tissues are shown in Figs. 3 (PYY) and
4 (enteroglucagon), for (a) controls compared to transections and (b) controls
compared to resections. In tissue samples of the control group, the PYY tissue
content was highest in the descending colon (327 ± 51 pmol/g), followed by the
terminal ileum (264 ± 24 pmol/g), rectum (180 ± 19 pmol/g), and the ascending
colon (156 ± 31 pmol/g). The transection groups were similar. The differences
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FIG.4.he etratedtissue enteroglucagon content (pmol/gram of tissue) in samples of
tissues from the (A) control and transection groups and from the (B) control and resection
groups. Results are shown as mean t SEM. When differences of mean enteroglucagon tissue
content of one group varied significantly from that ofcontrols, according to a Bartlett's test of
homogeneity and aTukey's test for significant differences between the means, this fact hasbeen
indicated by ** forp < 0.01.
within groups were only significant for thejejunal transection group, inwhich that of
the descending colon was significantly greater than all of the other segments
(413 + 33 pmol/g; Bartlett's,p < 0.0001; Tukey,p < 0.01). When comparing mean
PYY tissue contents of a particular bowel segment to that ofthe control group, only
the rectal tissue ofthe subtotal colectomy group, which was two- to threefold greater
than that of all other experimental groups, was significantly different (Bartlett's,
p < 0.0001; Tukey, p < 0.01). Although PYY content in the segments of colon
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which remained in the two hemicolectomy groups was greater than that of the
controls, the differences were not significant. The rectal and ileal tissue PYY
contents were similar to or less than those ofthe controls for the two hemicolectomy
groups.
The tissue content ofenteroglucagon was greatest in the terminal ileum (429 ± 30
pmol/g) and decreased in the ascending colon (243 ± 39 pmol/g), descending colon
(117 + 15 pmol/g), and rectum (43 + 4 pmol/g) in the control group. The results
were similar for the other groups. Specifically, the enteroglucagon content was
significantly greater (Bartlett's, p < 0.001; Tukey, p < 0.01) in the terminal ileum
than the other bowel segments, in the control, colonic transection, and subtotal
colectomy groups, and also in the jejunal transection group (Bartlett's,p < 0.0001;
Tukey, p < 0.05). Within all groups, the rectal tissue contained significantly less
(171 + 17 pmol/g; Bartlett's, p < 0.01; Tukey, p < 0.01) enteroglucagon than the
other bowel segments. When enteroglucagon levels of extracted bowel segments
from different groups were compared to those ofthe controls, only the rectal sample
from the subtotal colectomy group, which was three- to fourfold greater than all the
other groups, was significantly elevated (Bartlett's, p < 0.0001; Tukey, p < 0.01).
Although enteroglucagon content in the segments of colon which remained in the
two hemicolectomy groups was greater than that of the controls, the difference was
not significant. The rectal and ileal tissue enteroglucagon contentswere similar to or
less than those ofthe controls for the two hemicolectomy groups.
ImmunogoldDouble-LabelingofEndocrine Cells
Specific immunogold labeling was observed over epithelial endocrine cells both in
proximal colon and rectum. PYY and glucagon-like immunoreactivity (GLI) could
easily be distinguished from each other because of the different sizes of gold
particles. All cells labeled positively for PYY (n = 21) also labeled positively for
GLI. These cells contained round toslightlyovalgranuleswith a diameterof100-200
nm and were identified as L cells. The majority of PYY and GLI labeling was
observed over the granules in the same cells. This labeling was found to co-exist in a
majority of the granules. Enterochromaffin cells (n = 40) displayed no specific
labeling. When antisera were absorbed with an excess ofthe corresponding antigen,
no labeling was observed over L cells. Control sections showed no cross-reactivity
between the two immunogold detection systems.
DISCUSSION
We studied the serum and tissue levels of PYY and enteroglucagon in rats
following various large bowel resections. Plasma PYY levels following abdominal
(subtotal) colectomy were elevated more than fivefold over controls, and remained
significantly elevated throughout the 38 weeks of the study. The animals which
underwent transections or partial resections showed only transient increases in
circulating PYY levels, which quickly dropped to levels comparable to the control
group. In contrast to the plasma PYY changes, circulating levels of enteroglucagon
did not change significantly, with the exception of the right hemicolectomy group.
The tissue levels of PYY (two- to threefold greater) and enteroglucagon (three- to
fourfold greater) in the rectums of the rats with an abdominal colectomy were
significantly elevated as compared with all other experimental groups. Similarly,
there was a trend toward elevation of PYY and enteroglucagon in the remaining
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colonic tissue in the two partially resected groups. Finally, immunogold double-
labeling studies co-localized PYY and glucagon-like immunoreactivity (GLI) within
the same colonic L cells of the rectum and colon and within the same secretory
granules.
Plasma PYY levels were significantly elevated in the subtotal colectomy and right
hemicolectomy groups. One explanation for this response is the continued presence
of a significant intraluminal release stimulus to the endocrine tissue. For example,
infusion of bile salts and fatty acids into the lumen of the colon has been shown to
elevate plasma PYY [31,32]. More specifically, in studies with the isolated rabbit
colon, bile salts stimulated the release of PYY [33]. Following subtotal colectomy
and right hemicolectomy, with the loss of the terminal ileum and proximal colon,
larger quantities ofbile salts reach the distal gut mucosa [34]. In the right hemicolec-
tomy group, after a number ofweeks, the PYY levels returned to control levels, and,
in the subtotal colectomy groups, the PYY levels also began to fall by 38 weeks.
Perhaps there may be some ability of the small bowel or rectum to compensate for
the resected ileum and cecum. In contrast to these groups, the left hemicolectomy
group did not have ileum and cecum resected, and there was no protracted elevation
ofpeptides. Thus, alterations ofbile salts in the enteric contents arriving at the distal
bowel may be modulating the release ofPYY.
In the groups transected in thejejunum and in the mid-colon, significant transient
increases incirculating levelsofplasma PYYoccurred during the firstweekfollowing
surgery. A rise and fall oflesser magnitude was also observed for the plasma levels of
enteroglucagon during the same time period. Savage et al. observed a similar
transient rise in plasma levels of both peptides in rats having undergone a small
bowel resection [29]. Interestingly, the transient elevations of peptides, observed in
the first week of our studies, involved both PYY and enteroglucagon. The later
elevations ofcirculating peptides in the subtotal colectomy and right hemicolectomy
groups involved PYY only. The transient increases of both peptides may reflect
temporarydisruption ofgastrointestinal transit, allowingunabsorbed nutrients in the
distal gut [32,33,35,36]. The later elevations of plasma PYY may be a response to a
more PYY-specific releasing stimulus.
Both tissue PYY and enteroglucagon were elevated in the rectums ofthe subtotal
colectomy animals. There was also a trend toward elevation ofpeptide content in the
remaining colonic tissue ofthe partially resected groups, although this did not reach
significant levels. These changes in tissue peptide content suggest that a compensa-
tory mechanism may exist in the remaining endocrine tissue following resection. A
hyperfunctional state has been morphologically described by Buchan et al. in the
enteroglucagon-producing L cells following small bowel resection in rats [37]. This
state was characterized by increases in the morphologic area occupied by the rough
endoplasmic reticulum, but no significant change in cell size. Plasma enteroglucagon
was elevated in these animals [37]. Thus, it is possible that the elevated tissue and
circulating PYY observed in our study may be due to a similar hyperfunctional state
ofthe Lcells producing PYY.
The PYY and glucagon-like immunoreactivity (GLI) found within the same
colorectal L cells of rats indicates co-localization of PYY and enteroglucagon. Our
studies utilized an anti-glucagon antibody directed against both pancreatic glucagon
and enteroglucagon; however, more than 99 percent of GLI in the rat colon
represents enteroglucagon [6]. Thus, the immunogold labeling indicates that PYY
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and enteroglucagon are produced within the same endocrine cells of the rat colon
and rectum.
The co-localization ofPYY and enteroglucagon within the same colorectal L cells
of rats was in agreement with previous studies. In immunocytochemical studies of
serial sections of colon tissue, PYY and enteroglucagon co-localized in some
endocrine cells in rats and man [1,3]. Previous electron microscope work with
immunogold revealed both peptideswithin the same endocrine cells in cats and man
[5]. In our study, PYY and enteroglucagon co-localized in all cells examined, but this
finding does not exclude the possibility that separate populations ofcells containing
only PYY or glucagon exist.
In the subtotal colectomy group, both PYY and enteroglucagon content were
elevated in the rectum, while only a rise in plasma PYY occurred. The elevation in
rectal tissue content of both PYY and enteroglucagon could be explained by the
co-localization of PYY and enteroglucagon in the same L cells. The differential rise
of plasma PYY in these rats could indicate separate mechanisms of release. In
isolated colon experiments, for example, there was selective release of enterogluca-
gon in response to intraluminal oleic acid and release of PYY in response to
intraluminal bile salt [33]. Alternatively, the two peptides maybe cleared at different
rates.
Our results are similar to those observed in human studies. Besterman et al.
observed no significant difference in fasting and postprandial enteroglucagon levels
between patients withcolectomy (n = 9) and controls [38]. Our studyalso showed no
significant change in plasma enteroglucagon following colectomy. In other human
studies, Adrian et al. observed a significantly greater PYY incremental integrated
response to a meal, in colectomy patients (n = 5) compared with controls, but did
not find significant differences in fasting PYY levels and mean PYY levels [39].
These findingswere somewhat different from those ofourstudies,which showedthat
fastingplasma PYY levelswere elevated following colectomy. Perhaps the difference
in findings may be due to the variable amount of time after surgery in the human
studies. Furthermore, the data ofboth of the earlier human studies is more difficult
to interpret because of the inability to control for the amount ofbowel resected and
because of the use of inflammatory bowel disease patients. Inflammatory bowel
disease alters plasma and tissue levels of both PYY and enteroglucagon [40,41,42].
Thus, our studies and data from previous human studies indicate that PYY levels are
elevated while enteroglucagon levels are unchanged, following large bowel surgery.
Resection of distal segments ofgut which contain PYY may hinder digestion and
absorption offood in the small bowel. Infusion offat into the terminal ileum in man
slows both gastric emptying and intestinal transit [43]. The mechanism which
mediates this effect hasbeen called "the ileal brake." Since PYY inhibits gastric acid
and pepsinogen secretion, gastric emptying and small bowel transit, it has been
proposed that PYY mediates this mechanism [44]. PYY maybe released after meals
from the terminal ileum as well as the colon by postprandial increases of plasma
levels of cholecystokinin or by other neural mechanisms [45]. Our study did not
identify the mechanism which leads to increased plasma levels of PYY and tissue
levels of PYY and enteroglucagon following subtotal colectomy. These studies,
however, suggest that the colon may play a role in the mediation of the "ileal brake
mechanism" and that loss of the entire colon compromises this mechanism through
loss oftissue which normally releases PYY and enteroglucagon following meals. It is
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possible that, as a result ofshortened transit time, proximal digestion and absorption
is hindered and delivery to the distal gut increased of factors within the succus
entericus which stimulate PYY and enteroglucagon synthesis and release by L-type
endocrine cells. Elevated levels of PYY then improve proximal digestion and
absorption while enteroglucagon maypromote increased mucosal growth, leading to
returned normal function ofthe ileal brake mechanism. Additional studies, however,
will be required to test this possibility directly.
It is unlikely that the plasma and tissue elevations of PYY and enteroglucagon
observed in our studies reflect impaired health of or physiologic stress on the rats.
When using growth and survival as a marker for the general metabolic state of the
rats, the data indicate that all groups of rats were in an anabolic state. All
experimental rats continued to gain substantial amounts of weight throughout the
study. Similarly, the survival rate of the subtotal colectomy group (77 percent) from
the firstweek through the thirty-eighth weekwas at least as good as the right and left
hemicolectomy groups (56 percent and 78 percent, respectively). Furthermore, when
the effect of stress from serial blood sampling on plasma peptide levels was tested,
there were no significant differences observed.
This study demonstrated that plasma and tissue levels of the colonic hormones
PYY and enteroglucagon are altered following colonic resections. These results
suggest that functional outcome following colonic resections may be effected by
subsequent growth and function of colonic endocrine cells. Further study of these
and other colonic peptides mayyield useful information to apply in the treatment of
patients with inflammatory bowel disease or patients who have undergone small and
large bowel resections.
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